In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome solution and expanded clinical sequencing services, including supporting Florida State University’s new pediatric rare ...

The market misinterprets past COVID-era revenue growth for 10x Genomics and fails to integrate current sector growth. Read ...

Quanterix remediated all cited material weaknesses in its control environment during the quarter, solidifying its compliance foundation. The newly consolidated enterprise stands more diversified, with ...

In a single experiment, scientists can decipher the entire genomes of many patient samples, animal models, or cultured cells.

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.

Illumina’s fair value estimate has been adjusted slightly, moving from US$135.94 to US$136.05, signaling only a very modest change in the modeled price target. That small shift sits against a backdrop ...

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...

To use this evidence, investigators typically must grow the larvae until adulthood in a laboratory setting and then identify ...